The VA National Acquisition Center is preparing to issue Request for Proposal (RFP) 36E79725R0041 for an unrestricted procurement of Metformin HCL IR Tablets to supply the Department of Veterans Affairs, Department of Defense, Bureau of Prisons, Indian Health Service, and other federal health entities. The contract will be awarded to a responsible offeror capable of ensuring an uninterrupted supply for one year, with four additional one-year options available. Offerors must provide the exact drug name and a unique National Drug Code (NDC), ensuring their label is the sole identifier on the product. The solicitation is set to be issued electronically in compliance with FAR Part 12 around April 14, 2025, with a closing date of April 29, 2025. Interested parties should refer to SAM.gov for updates and amendments, as paper copies will not be distributed. Teresa Hussain is the main point of contact for any inquiries regarding this procurement.

The document outlines the solicitation for a contract with the Department of Veterans Affairs (VA) regarding the supply of Metformin HCL IR Tablets as part of the pharmaceutical prime vendor programs for both the VA and the Department of Defense (DoD). It specifies the necessary proposal submissions, including pricing for various bottle sizes and quantities, adherence to FDA regulations, and strict compliance with the Drug Supply Chain Security Act (DSCSA). Offerors must provide a unique National Drug Code (NDC) for each product and must include a 0.5% Cost Recovery Fee in their prices. The contract will have an implementation period followed by a one-year ordering period with up to four additional one-year options. Offerors must prove the availability of supply sources, specifically if they are distributors, and ensure all products meet FDA Good Manufacturing Practices (cGMP). The document details requirements for backorders, recalls, product registration, and consent for manufacturing facilities. Overall, the solicitation aims to establish a reliable source for pharmaceutical products, ensuring consistent availability and pricing while adhering to federal regulations and participation requirements from various government entities.

The document outlines a federal Request for Proposal (RFP) from the Department of Veterans Affairs (VA) seeking bids for the supply of Metformin HCL IR Tablets across various dosages in collaboration with the Department of Defense (DoD) Pharmaceutical Prime Vendor Programs. It emphasizes the need for offerors to price products competitively for a base year and four optional years, incorporating a 0.5% Cost Recovery Fee. Offerors must provide unique National Drug Code (NDC) numbers for all proposed drug products and maintain compliance with FDA's Good Manufacturing Practices (cGMP). The RFP establishes a framework for order fulfillment through Prime Vendors, with stringent requirements for product availability, reporting, and barcoding. The contract aims to streamline procurement processes for VA and DoD, ensuring consistent drug supply across healthcare facilities. It includes sections on compliance, product safety, registration, and recall procedures, highlighting the need for a commitment to quality and regulatory standards throughout the contract duration. Overall, the document serves as a formal solicitation of vendors capable of meeting the specifications for pharmaceutical supplies, reflecting the government's objective to procure necessary drugs efficiently and at competitive pricing to support veteran and military healthcare needs.